---
title: "Xapien’s $56M Series B: Spectrum Bets on Always-On Due Diligence"
description: "Spectrum Equity led Xapien’s $56 million Series B on September 11, 2026. The AI due-diligence platform claims 350%+ ARR growth over 24 months, 350 clients in 15 countries, and half of revenue already from the U.S."
date: 2026-09-11T00:00:00.000Z
tags: ["2026-vc-news", "startup-funding", "venture-capital", "compliance-tech", "enterprise-saas"]
source: https://venturecapitaltracker.com/2026-xapien-56m-series-b-spectrum-due-diligence-ai
---

# Xapien’s $56M Series B: Spectrum Bets on Always-On Due Diligence

> Spectrum Equity led Xapien’s $56 million Series B on September 11, 2026. The AI due-diligence platform claims 350%+ ARR growth over 24 months, 350 clients in 15 countries, and half of revenue already from the U.S.

**[Xapien](/startup/xapien)** raised **$56 million** Series B financing announced **September 11, 2026**, led by **Spectrum Equity**, with existing investor **YFM Equity Partners** returning. Axios labels the round Series B; the company calls it a growth investment. Valuation was **not disclosed**. Use of proceeds: expand the **U.S.** presence (already **50%** of revenue), grow the Boston office, and relocate the CEO and other leaders ([company](https://xapien.com/news-and-events/xapien-secures-56-million-to-scale-dynamic-due-diligence-globally/), [Axios](https://www.axios.com/pro/all-deals/2026/09/10/due-diligence-ai-xapien-56-million)).

**Spine:** Compliance teams still ration diligence to a fraction of counterparties. Xapien is selling full coverage plus continuous monitoring — and Spectrum’s World-Check / Verafin pattern recognition is the investor tell.

## Key facts

| Field | Detail |
| --- | --- |
| Company | [Xapien](/startup/xapien) ([xapien.com](https://xapien.com)) — London-founded, Boston expansion |
| Round | **$56M** Series B (Axios) / growth investment (company) |
| Lead | Spectrum Equity (Adam Margolin quoted) |
| Returning | YFM Equity Partners (led 2024 Series A) |
| Traction (company) | **350%+** ARR growth over **24 months**; **350** clients/partners in **15** countries; U.S. **50%** of revenue |
| Named logos | Greenberg Traurig, ABB, Dow Jones Risk & Compliance, KPMG |
| Prior | **$10M** Series A / **£8M** (July 2024) led by YFM; total then **$17.8M** |
| Valuation | **Not disclosed** |

## Who uses the product — and for what job

**Users:** compliance, legal, and procurement teams inside multinational corporations, law firms, private banks, universities, nonprofits, and professional-services firms that automate research for clients.

**Job:** turn open-web + registry + sanctions + media into a **sourced, auditable** counterparty report in minutes, then (via **Xapien Live** beta) keep watching risk after onboarding.

Company claim: clients report **90%** of onboarding cases can be fully automated so analysts focus on complex/high-risk files. Treat as **customer-reported**, not audited. The company cites industry bandwidth pain — only **30%** of organizations say they can assess even half of relationships — as the coverage gap it sells into.

## Why now

- Agent-era business moves faster than static KYC packets; one-off onboarding checks leave **unmonitored** third-party risk.
- Spectrum’s risk-tech portfolio (World-Check, Verafin, and peers named in the release) signals a category buyer who knows compliance distribution.
- U.S. already half of revenue — the raise is a **relocation / go-to-market** bet, not a first beachhead.

## Why Spectrum — portfolio fit

Spectrum Equity specializes in growth software with risk-and-compliance DNA. Leading $56M after YFM’s Series A fits a **category-standard** thesis: automation that still clears audit bars. *Spectrum Equity and YFM have no `/fund/` pages here — editorial only.*

YFM returning is continuity capital, not a new logo hunt.

## Competitive map

| Approach | Tradeoff |
| --- | --- |
| Manual research / Big Four projects | Depth; rationed coverage |
| Legacy screening lists alone | Fast hits; weak narrative risk |
| Generic LLM research | Speed; weak audit trail / entity resolution |
| Xapien AI + continuous Live | Throughput + monitoring; must prove accuracy at scale |

## What is not proven

- Valuation, absolute ARR, and churn.
- How often “90% automated” holds outside named design partners.
- Whether Live exits beta with the same trust bar as point-in-time reports.

## Practical takeaway

- **Founders (RegTech):** Sell **coverage × continuous monitoring**, not “AI that writes memos.”
- **Investors:** Diligence false-positive rates and analyst time saved vs. legacy stacks.
- **Operators:** Relevant if you still sample counterparties because bandwidth — not appetite — is the constraint.

### Sources

1. [Xapien — $56M](https://xapien.com/news-and-events/xapien-secures-56-million-to-scale-dynamic-due-diligence-globally/)
2. [Axios Pro](https://www.axios.com/pro/all-deals/2026/09/10/due-diligence-ai-xapien-56-million)
3. [Legal IT Insider](https://legaltechnology.com/xapien-raises-56m-funding-round/)
4. [Xapien — 2024 Series A](https://xapien.com/news-and-events/xapien-secures-10m-in-series-a-funding-to-drive-ai-powered-transformation-of-research-industry/)

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.